CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial. He W, Eriksson M, Eliasson E, Grassmann F, et al. Ann Oncol 2021;32:1286-1293.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

He W, Eriksson M, Eliasson E, Grassmann F, et al. CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial. Ann Oncol 2021;32:1286-1293.
PMID: 34284099